FDA Extends Agios' Mitapivat Sickle Cell Disease Review; New PDUFA Date Set; Stock Down

Agios Pharmaceuticals (AGIO) reported a three-month extension in the FDA's review of mitapivat for sickle cell disease, with a new PDUFA date of February 1, 2027. The extension follows additional information requested by the FDA, including updated safety data. AGIO shares are down 17.55% to $30.69.

Original reporting
Published Oct 30, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$AGIO
Bearish
high confidence
Mentioned
$AGIO
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$AGIOBearishMed
01

Why it matters

Regulatory delay pushes back commercial launch, affecting revenue expectations.

02

Market read

The extension is a material regulatory event for a mid‑cap biotech, likely keeping the stock under pressure in the short term.

03

What to watch

Potential positive data from the REIGNITE Phase 3 trial could offset the delay.

Relevance 7/10Novelty 7/10Timing: today

Background

Agios Pharmaceuticals is developing mitapivat for sickle cell disease; the drug is already approved for other indications.

Company-level read

Ticker impact

$AGIOBearishHigh confidence
Context

FDA extended the review of Agios' mitapivat sNDA for sickle cell disease, setting a new PDUFA date of Feb 1 2027; shares fell 17.5% after the announcement.

Expected impact

downward pressure as the market prices in the delayed timeline

Evidence & confidence

Regulatory timeline extensions typically depress biotech stocks until a clear path forward is re‑established.

Market effects

May weigh on other rare‑disease biotech stocks awaiting FDA decisions.

Limited to US biotech sector; no broader market effect.

Minimal global impact beyond investors tracking FDA pipelines.

Counterpoint

If the FDA later grants approval, the stock could rally on a longer runway.

Key entities

  • Agios Pharmaceuticals

    Biotech firm developing mitapivat.

  • FDA

    U.S. Food and Drug Administration overseeing the review.

Related articles

$AGIOMed

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

$AGIOMed

Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue surged 4x, but faced a 3-month FDA review delay for mitapivat in sickle cell disease, increasing uncertainty. Net loss narrowed to $65M from $103.4M YoY. Selling expenses rose to $56.5M, and no 2027 guidance was provided. Thalassemia launch growth may moderate, with 177 prescriptions as a new run rate. Pipeline programs remain early-stage.

$AGIOMed

Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Agios Pharmaceuticals reported Q3 2026 revenue of $55.4M, driven by mitapivat in thalassemia. The company plans to cut R&D headcount by 35% to focus on rare hematology and aims for non-GAAP profitability in 2028. Mitapivat's sickle cell disease approval was delayed to February 2027 due to FDA review. The company is also advancing AG-236 for polycythemia vera and cevidoplenib for immune thrombocytopenia.

$AGIOMed

Agios (AGIO) Q3 2026 Earnings Call Transcript

Agios (AGIO) reported Q3 2026 earnings, highlighting $55.4M in mitapivat revenue, a 3-month FDA review extension for sickle cell disease, and $907M in cash. The company plans to reduce R&D headcount by 35% and aims for non-GAAP profitability in 2028. Mitapivat saw a 4x revenue increase YoY, with strong U.S. and international demand.

$AGIOHigh

Truist cuts Agios Pharma stock price target on SCD concerns

Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.

$AGIOHigh

Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue of $55.4M for mitapivat products, up over fourfold YoY. U.S. revenue rose to $48.7M, while ex-U.S. revenue increased to $6.6M. Net loss narrowed to $65.0M. The FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027. Agios plans to reduce R&D workforce by over 35% by year-end 2026.